Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Moexipril/hydrochlorothiazide 15 · 2 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Moexipril HCl/hydrochlorothiazide 15/25 mg tablets | DRUG | 1 x 15/25 mg |
| UNIRETIC® 15/25 mg tablets | DRUG | 1 x 15/25 mg |
Inclusion Criteria: * All subjects selected for this study will be non-smokers at least 18 years of age. * Subjects will have a BMI index (body mass index) of 30 or less. Exclusion Criteria: * Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious...
Moexipril/hydrochlorothiazide 15 is an investigational small molecule being studied in healthy volunteers. It is a combination product containing moexipril and hydrochlorothiazide, and it is currently in Phase 1 clinical development. The drug is being evaluated for its pharmacokinetic profile under fasting and non-fasting conditions.
Moexipril/hydrochlorothiazide 15 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker TEVA. Teva is conducting Phase 1 clinical trials to evaluate the drug's behavior in healthy subjects.
Moexipril/hydrochlorothiazide 15 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, both involving healthy volunteers in the United States.
Moexipril/hydrochlorothiazide 15 has two completed Phase 1 trials. NCT00834067 evaluated the drug under non-fasting conditions, and NCT00835042 evaluated it under fasting conditions. Each trial enrolled 60 healthy adults aged 18 years and older in the United States.
Moexipril/hydrochlorothiazide 15 is a combination product that contains moexipril and hydrochlorothiazide. It is being studied as a fixed-dose tablet, with the trials specifically testing the 15/25 mg strength. The drug is in Phase 1 development for healthy volunteers.